Acutus medical completes enrollment in ide trial with its acqblate® force sensing ablation system

Carlsbad, calif., may 13, 2022 (globe newswire) -- acutus medical (nasdaq: afib), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company's acqforce™ flutter investigational device exemption (ide) clinical trial which enrolled 110 patients at 21 sites globally.
AFIB Ratings Summary
AFIB Quant Ranking